NCI Benchmarks |  |
A New Delivery for Cancer Drugs
The protein tumor necrosis factor-alpha (TNF-alpha) is a powerful weapon in the arsenal to control cancer. Unfortunately, as is the case with many potent cancer therapies, the use of TNF-alpha as an anti-cancer therapy has been severely limited. “It was so toxic that it caused death,” and researchers gave up on it, explains Scott [...]
Anuradha Budhu
Anuradha Budhu, Ph.D., heads a research team at the National Cancer Institute that recently uncovered an imbalance between saturated and unsaturated fats (such as palmitic or fatty acids) that occur in patients with a common liver cancer called hepatocellular carcinoma, or HCC. Budhu’s team also determined that HCC patients with high unsaturated fat levels had [...]
NCI Grantees Receive Breakthrough Prizes in Life Sciences
The Breakthrough Prize in Life Sciences recognizes “excellence in research aimed at curing intractable diseases and extending human life.” The inaugural set of prizes, awarded in February 2013 by a not-for-profit corporation dedicated to advancing breakthrough research, are backed by well-known personalities such as Sergey Brin, Google co-founder and his wife, Anne Wojcicki, co-founder of [...]
 EurekAlert! - Cancer | |
Researchers identify first drug targets in childhood genetic tumor disorder
(The Mount Sinai Hospital / Mount Sinai School of Medicine) Two mutations central to the development of infantile myofibromatosis -- a disorder characterized by multiple tumors involving the skin, bone, and soft tissue -- may provide new therapeutic targets, according to researchers from the Icahn School of Medicine at Mount Sinai. The findings, published in The American Journal of Human Genetics, may lead to new treatment options for this debilitating disease, for which the only current treatment option is repeated surgical removal of the tumors.
New fluorescent tools for cancer diagnosis
(Journal of Clinical Investigation) In this issue of the Journal of Clinical Investigation, Thomas Tuschl and colleagues at Rockefeller University developed a multicolor fluorescence labeling method that can be used to visualize miRNAs in tissue sections, such as those recovered from biopsies.
Modulating the immune system to combat metastatic cancer
(Journal of Clinical Investigation) In this issue of the Journal of Clinical Investigation, researchers led by Ronald Levy at Stanford University found that regulatory T cells that infiltrate tumors express proteins that can be targeted with therapeutic antibodies.
|
.jpg&new_width=120)